# Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

> **NCT05335473** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 87 (estimated)

## Conditions studied

- HR Positive HER2 Negative Advanced Breast Cancer

## Interventions

- **DRUG:** Eribulin and Tucidinostat

## Key facts

- **NCT ID:** NCT05335473
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-13
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-11-01
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05335473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05335473, "Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT05335473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*